Opinion
No. 2D21-1188
10-20-2021
CVS PHARMACY, Petitioner, v. STATE of Florida, Office of the Attorney General, Department of Legal Affairs; Purdue Pharma L.P., Purdue Pharma, Inc. ; The Purdue Frederick Company, Inc.; Endo Health Solutions, Inc.; Endo Pharmaceuticals, Inc. ; Janssen Pharmaceuticals, Inc.; Johnson & Johnson, Cephalon, Inc.; Teva Pharmaceuticals USA, Inc. ; Allergan Finance, LLC; Actavis Pharma, Inc.; Actavis LLC, Insys Therapeutics, Inc.; Amerisourcebergan Drug Corporation; Cardinal Health, Inc.; McKesson Corporation; Mallinckrodt LLC; Walgreen Co. ; and C.V.S. Healthcare Corp. Respondents.
Marcos E. Hasbun, Nathan Berman, and Daniella R. Sterns of Zuckerman Spaeder LLP, Tampa, for Petitioner. Ashley Moody, Attorney General; John Guard, Chief Deputy Attorney General; Gregory S. Slemp, Special Counsel for Litigation; R. Scott Palmer, Chief of Complex Enforcement; Nicholas D. Niemiec and Lee Istrail, Assistant Attorneys General, Tallahassee; and David C. Frederick, Ariela M. Migdal, and Thomas G. Schultz of Kellogg, Hansen, Todd, Figel & Frederick, P.L.L.C, Washington, D.C. for Respondent, State of Florida, Office of the Attorney General, Department of Legal Affairs. Joshua C. Webb and Dennis P. Waggoner of Hill, Ward Henderson, P.A., Tampa, for Respondent, Allergan Finance, LLC. Benjamin C. Block of Covington & Burling LLP, Washington, DC, for McKesson Corp. No appearance for remaining Respondents.
DECISION WITHOUT PUBLISHED OPINION
Dismissed.